Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 478-490

  Gupta, Umesh ^a   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

AIDS; Liposomes; Nanocarrier in Anti HIV; Nanotechnology

Indexed keywords

ANTI-HIV; CONVENTIONAL DRUGS; ETHOSOMES; FORMULATION DEVELOPMENT; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HIV/AIDS; LIFE SPAN; NANOCARRIER IN ANTI HIV; NANOCARRIERS; NON-POLYMERIC; POLYMERIC CARRIERS; SOLID LIPID NANOPARTICLES; SYNTHETIC PATHWAYS;

DENDRIMERS; DRUG DELIVERY; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; PHOSPHOLIPIDS; VIRUSES;

DISEASES;

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DENDRIMER; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LIPOSOME; LOPINAVIR; LOVIRIDE; MYRISTIC ACID; NANOCARRIER; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DENDRITIC CELL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HYDROPHILICITY; HYPERSENSITIVITY; INFECTION CONTROL; INSOMNIA; LACTIC ACIDOSIS; LIVER FAILURE; MACROPHAGE; MALAISE; MORBIDITY; MORTALITY; NANOEMULSION; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NEUROPATHY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PHOSPHORYLATION; PRIORITY JOURNAL; RETROVIRUS; REVIEW; VIRION; VIRUS GENOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; LIPIDS; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; POLYMERS; SUSPENSIONS;

EID: 76849101594     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.018     Document Type: Review

References (155)

1. Ingraham J.L., and Ingraham C.A. Introduction to microbiology. IInd Edition (2000), Wadsworth Pub. Co, California 336
2. Janse van Rensburg E. The origin of HIV. S. Afr. J. Sci. 96 (2000) 267-269
3. CDC (Centers for Disease Control). Updates on aquired immune deficiency syndrome (AIDS) - United States. MMWR 31 (1982) 507-514
4. Ojewale E., Mackraj I., Naidoo P., and Govender T. Exploring the use of novel drug delivery systems for antiretrtroviral drugs. Eur. J. Pharm. Biopharm. 70 (2008) 697-710
5. http://www.avert.org/worldstats.htm (downloaded on 10.05.2009).
6. Gallo R.C., and Montagnier L. The chronology of AIDS research. Nature 326 (1987) 435-436
7. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kalpan M., Haynes B.F., Palker T.J., Redfield R., Oleske J., and Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 (1984) 500-503
8. Popovic M., Sarngadharan M.G., Read E., and Gallo R.C. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224 (1984) 497-500
9. Gallo R.C., and Reitz Jr. M.S. Human retroviruses and adult T-cell leukemia-lymphoma. J. Natl. Cancer Inst. 69 (1982) 1209-1214
10. Levy J.A., Hoffman A.D., Kramer S.M., Landis J.A., Shimabukuro J.M., and Oshiro L.S. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225 (1984) 840-842
11. Wofsy C.B., Cohen J.B., Hauer L.B., Padian N.S., Michaelis B.A., Evans L.A., and Levy J.A. Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet 8 (1986) 527-529
12. Wain-Hobson S., Sonigo P., Danos O., Cole S., and Alizon M. Nucleotide sequence of the AIDS virus, LAV. Cell 40 (1985) 9-17
13. Ratner L., Gallo R.C., and Wong-Stall F. HTLV-II, LAV, ARV are variant of same AIDS virus. Nature 313 (1985) 636
14. Sanchez-Pescador R., Power M.D., Barr P.J., Steimer K.S., Stempien M.M., Brown-Shimer S.L., Gee W.W., Renard A., Randolph A., and Levy J.A. Nucleoside sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227 (1985) 484-492
15. Coffin J., Haase A., Levy J.A., Montagnier L., Oroszlan S., Teich N., Temin H., Toyoshima K., Varmus H., and Vogt P. Human immunodeficiency viruses. Science 232 (1986) 697
16. Fauci A.S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 239 (1988) 617-622
17. Temin H.M. Mechanisms of cell killing/cytopathic effects by nonhuman retroviruses. Rev. Infect. Dis. 10 (1988) 399-405
18. Temin H.M., and Is H.I.V. unique or merely different?. J. Acquir. Immune Defic. Syndr. 2 (1989) 1-9
19. Stowring L., Haase A.T., and Charman H.P. Serological definition of the lentivirus group of retroviruses. J. Virol. 29 (1979) 523-528
20. Gonda M.A., Wong-Staal F., Gallo R.C., Clements J.E., Narayan O., and Gilden R.V. Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathologic lentivirus. Science 227 (1985) 173-177
21. Haase A.T. Pathogenesis of lentivirus infections. Nature 322 (1986) 130-136
22. Weiss R.A. Cellular receptors and viral glycoproteins involved in retrovirus entry. In: Levy J.A. (Ed). The Retroviridae (1993), Plenum Press, New York 1-108
23. Moore J.P., Jameson B.A., Weiss R.A., and Sattentau Q.J. The HIV-cell fusion reaction. In: Bentz J. (Ed). Viral Fusion Mechanisms (1993), CRC, Boca Raton, Florida 233-290
24. Clapham P.R., and McKnight A. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83 (2002) 1809-1829
25. Farnet C.M., and Haseltine W.A. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J. Virol. 65 (1991) 1910-1915
26. Popov S., Rexach M., Zybarth G., Reiling N., Lee M.A., Ratner L., Lane C.M., Moore M.S., Blobel G., and Bukrinsky M. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J. 17 (1998) 909-917
27. Le Rouzic E., and Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2 (2005) 11
28. Haffar O., and Bukrinsky M. Nuclear translocation as a novel target for anti-HIV drugs. Expert Rev. Anti-Infect. Ther. 3 (2005) 41-50
29. Van Maele B., and Debyser Z. HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev. 7 (2005) 26-43
30. Bushman F.D. Integration site selection by lentiviruses: biology and possible control. Curr. Top. Microbiol. Immunol. 261 (2002) 165-177
31. Schroeder A., Shinn P., Chen H., Berry C., Ecker J., and Bushman F. HIV-genome integration in one the human genome favors active genes and hotspots. Cell 110 (2002) 521
32. Nguyen D.H., and Hildreth J. Evidence for budding of human immunodeficiency virus type 1 selectivity from glycolipid-enriched membrane lipid rafts. J. Virol. 74 (2000) 3264-3272
33. Ono A., and Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl Acad. Sci. USA 98 (2001) 13925-13930
34. Freed O. Viral late domains. J. Virol. 76 (2002) 4679-4687
35. Gould S.J., Booth A.M., and Hildreth J.E. the Trojan exosome hypothesis. Proc. Natl Acad. Sci. USA 100 (2003) 10592-10597
36. Schrager L.K., and D'Souza M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. J. Am. Med. Assoc. 280 (1998) 67-71
37. Sierra S., Kupfer B., and Kaiser R. Basics of virology of HIV-1 and its replication. J. Clin. Virol. 34 (2005) 233-244
38. Zeldin R.K., and Petruschke R.A. Pharmacological and therapeutic properties of retonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53 (2004) 4-9
39. Clercq E.D. HIV chemotherapy and prophylaxis: new drugs, leads and approaches. Int. J. Biochem. Cell Biol. 36 (2004) 1800-1822
40. Menne S., Butler S.D., George A.L., Tochkov I.A., Zhu Y., Xiong S., Gerin J.L., Cote P.J., and Tennant B.C. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 52 (2008) 3617-3632
41. Clercq E.D. New ant-HIV agents and targets. Med. Res. Rev. 22 (2002) 531-565
42. Reinke R.A., King P.J., Victoria J.G., McDougall B.R., Ma G., Mao Y., Reinecke M.G., and Robinson Jr. W.E. Dicaffeoyltartaric acid analogues inhibit Human Immunodeficiency Virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations. J. Med. Chem. 45 (2002) 3669-3683
43. King P.J., and Robinson Jr. W.E. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 72 (1998) 8420-8424
44. Clercq E.D. New developments in anti-HIV chemotherapy. II Farmaco 56 (2001) 3-12
45. Highleyman L. HIV drugs and the HIV lifecycle (2003). http://www.thewellproject.org/en_US/Treatmentand_Trials/Anti_HIV_Meds/Lifecycle_and_ARVs.jsp Available from: < http:// www.thewellproject.org/en_US/Treatmentand_Trials/Anti_HIV_Meds/Lifecycle_and_ARVs.jsp> (downloaded on 10.05.2009)
46. Pieribone D. The HIV life cycle (2002/2003). http://www.thebody.com/content/art14193.html Available from: (downloaded on 10.05.2009)
47. Shahiwala A., and Amiji M.M. Nanotechnology based delivery systems in HIV/AIDS therapy. Future HIV Ther. 1 (2007) 49.59
48. Vyas T.K., Shah L., and Amiji M.M. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug. Deliv. 3 (2006) 613-628
49. Amiji M.M., Vyas T.K., and Shah L.K. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov. Med. 6 (2006) 157-162
50. Li X.L., and Chan W.K. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv. Drug Deliv. Rev. 39 (1999) 81-103
51. Xiang J., Fang X., and Li X. Transbuccal delivery of 2', 3'-dideoxycytidine: in vitro permeation study and histological investigation. Int. J. Pharm. 231 (2002) 57-66
52. Mirchandani H., and Chien Y.W. Drug delivery approaches for anti-HIV drugs. Int. J. Pharm. 95 (1993) 1-21
53. Gupta U., Agashe H.B., Asthana A., and Jain N.K. Dendrimers: novel polymeric nano-architectures for solubility enhancement. Biomacromolecules 7 (2006) 649-658
54. Covreur P., and Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23 (2006) 1417-1450
55. Lockman P., Mumper R., Khan M., and Allen D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 28 (2002) 1-13
56. Nahar M., Dutta T., Murugesan S., Asthana A., Mishra D., Rajkumar V., Tare M., Saraf S., and Jain N.K. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther. Drug Carrier Syst. 23 (2006) 259-318
57. Satija J., Gupta U., and Jain N.K. Pharmaceutical and biomedical potential of surface engineered dendrimers. Crit. Rev. Ther. Drug Carrier Syst. 24 (2007) 261-315
58. Weiss R.A. How does HIV cause AIDS. Science 260 (1993) 1273-1279
59. Schafer V., von Briesen H., Andreesen R., Steffan A.M., Royer C., Troster S., Kreuter J., and Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9 (1992) 541-546
60. Lobenberg R., Araujo L., Von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 (1998) 21-30
61. Bender A.R., Von Briesen H., Kreuter J., Duncan I.B., and Rubsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40 (1996) 1467-1471
62. Kuo Y.C., and Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327 (2006) 160-169
63. Kuo Y.C., and Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate methyl methacrylate sulfopropyl methacrylate and solid lipid nanoparticles. Int. J. Pharm. 340 (2007) 143-152
64. Agrawal P., Gupta U., and Jain N.K. Glycoconjugated Peptide dendrimers based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28 (2007) 3349-3359
65. Singh P., Gupta U., Asthana A., and Jain N.K. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization and targeted anticancer drug delivery potential in tumor induced mice. Bioconjug. Chem. 19 (2008) 2239-2252
66. Gupta U., Agashe H.B., and Jain N.K. Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. J. Pharm. Pharm. Sci. 10 (2007) 358-367
67. Gupta U., Agashe H.B., Asthana A., and Jain N.K. A review of in vitro-in vivo investigations on dendrimers: the novel nanoscopic drug carriers. Nanomed. Nanotech. Biol. Med. 2 (2006) 66-73
68. Agarwal A., Gupta U., Asthana A., and Jain N.K. Dextran conjugated dendrtitic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials 30 (2009) 3588-3596
69. Bhadra D., Bhadra S., Jain S., and Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257 (2003) 111-124
70. Kumar P.V., Asthana A., Dutta T., and Jain N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target. 14 (2006) 546-556
71. Chauhan A.S., Sridevi S., Chalasani K.B., Jain A.K., Jain S.K., Jain N.K., and Diwan P.V. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Release 90 (2003) 335-343
72. Esfand R., and Tomalia D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6 (2001) 427-436
73. Tekade R.K., Kumar P.V., and Jain N.K. Dendrimers in oncology: an expanding horizon. Chem. Rev. 109 (2009) 49-87
74. Dutta T., and Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 1770 (2007) 681-686
75. Dutta T., Agashe H.B., Garg M., Balasubramanium P., Kabra M., and Jain N.K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 15 (2007) 89-98
76. Dutta T., Garg M., and Jain N.K. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 34 (2008) 181-189
77. Castor T.P. Phospholipid nanosomes. Curr. Drug Deliv. 2 (2005) 329-340
78. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57 (2005) 637-651
79. Voinea M., and Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J. Cell. Mol. Med. 6 (2002) 465-474
80. Agrawal A.K., and Gupta C.M. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug. Deliv. Rev. 41 (2000) 135-146
81. Kozubek A., Gubernator J., Przeworska E., and Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim. Pol. 47 (2000) 639-649
82. Sharma A., and Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154 (1997) 123-140
83. Desormeaux A., and Bergeron M.G. Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. J. Drug Target. 6 (1998) 1-15
84. Prior S., Gander B., Blarer N., Merkle H.P., Subira M.L., Irache J.M., and Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 15 (2002) 197-207
85. Karlowsky J.A., and Zhanel G.G. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin. Infect. Dis. 15 (1992) 654-667
86. Vitas A.I., Díaz R., and Gamazo C. Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrob. Agents Chemother. 40 (1996) 146-151
87. Katragadda A., Bridgman R., and Betageri G. Effect of liposome composition and cholesterol on the cellular uptake of stavudine by human monocyte/macrophages. Cell. Mol. Biol. Lett. 5 (2000) 483-493
88. Ahsan F., Rivas I.P., Khan M.A., and Torres Suárez A.I. Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release 79 (2002) 29-40
89. Lanao J.M., Briones E., and Colino C.I. Recent advances in delivery systems for anti-HIV1 therapy. J. Drug Target. 15 (2007) 21-36
90. Szebeni J., Wahl S.M., Betageri G.V., Wahl L.M., Gartner S., Popovic M., Parker R.J., Black C.D., and Weinstein J.N. Inhibition of HIV-1 in monocyte/ macrophage cultures by 2', 3'-dideoxycytidine-5'-triphosphate, free and in liposomes. AIDS Res. Hum. Retroviruses 6 (1990) 691-702
91. Betageri G.V., and Burrell L.S. Stability of antibody-bearing liposomes containing dideoxyinosine triphosphate. Int. J. Pharm. 98 (1993) 149-155
92. Phillips N.C., Skamene E., and Tsoukas C. Liposomal encapsulation of 3`-azido-3`- deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression. J. Acquir. Immune Defic. Syndr. 4 (1991) 959-966
93. Phillips N.C., and Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79 (1992) 1137-1143
94. Jain S., Tiwary A.K., and Jain N.K. Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. Curr. Drug Deliv. 3 (2006) 157-166
95. Jain S., Tiwary A.K., and Jain N.K. PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr. Drug Deliv. 5 (2008) 275-281
96. Jin S.X., Bi D.Z., Wang J., Wang Y.Z., Hu H.G., and Deng Y.H. Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie 60 (2005) 840-843
97. Vyas S.P., Subhedar R., and Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J. Pharm. Pharmacol. 58 (2006) 321-326
98. Wu H.B., Deng Y.H., Wang S.N., Zhou X.Y., Wang N., and Shi L. The distribution of azidothymidine palmitate galactosylated liposomes in mice. Acta Pharm. Sin. 42 (2007) 538-544
99. Garg M., and Jain N.K. Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J. Drug Target. 14 (2006) 1-11
100. Kaur C.D., Nahar M., and Jain N.K. Lymphatic targeting of zidovudine using surface-engineered liposomes. J. Drug Target. 16 (2008) 798-805
101. Garg M., Asthana A., Agashe H.B., Agrawal G.P., and Jain N.K. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 58 (2006) 605-616
102. Garg M., Dutta T., and Jain N.K. Stability study of stavudine-loaded O-palmitoyl-anchored carbohydrate-coated liposomes. AAPS PharmSciTech 8 (2007) E1-E8
103. Garg M., Dutta T., and Jain N.K. Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm. 67 (2007) 76-85
104. Garg M., Garg B.R., Jain S., Mishra P., Sharma R.K., Mishra A.K., Dutta T., and Jain N.K. Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes. Eur. J. Pharm. Sci. 33 (2008) 271-281
105. Faulds D., and Brogden R.N. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44 (1992) 94-116
106. Ray G.F., Mason W.D., and Badr M.Z. Pharmacokinetics of the anti-AIDS drug 2', 3'-dideoxyinosine in the rat. Drug Metab. Dispos. 18 (1990) 654-658
107. Désormeaux A., Harvie P., Perron S., Makabi-Panzu B., Beauchamp D., Tremblay M., Poulin L., and Bergeron M.G. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2', 3'-dideoxyinosine. AIDS 8 (1994) 1545-1153
108. Harvie P., Desormeaux A., Gagne N., Tremblay M., Poulin L., Beauchamp D., and Bergeron M.G. Lymphoid tissues targeting of liposome-encapsulated 2', 3'- dideoxyinosine. AIDS 9 (1995) 701-707
109. Harvie P., Desormeaux A., Bergeron M.C., Tremblay M., Beauchamp D., Poulin L., and Bergeron M.G. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2', 3'-dideoxyinosine. Antimicrob. Agents Chemother. 40 (1996) 225-229
110. Kompella U.B., Aukunuru J.V., and Betageri G.V. Effect of neutral liposomes on corneal and conjunctival transport of didanosine. Drug Deliv. 6 (1999) 9-14
111. Lalanne M., Paci A., Andrieux K., Dereuddre-Bosquet N., Clayette P., Deroussent A., Ré M., Vassal G., Couvreur P., and Desmaële D. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 17 (2007) 2237-2240
112. Lalanne M., Andrieux K., Paci A., Besnard M., Ré M., Bourgaux C., Ollivon M., Desmaele D., and Couvreur P. Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. Int. J. Pharm. 344 (2007) 62-70
113. Kim S., Scheerer S., Geyer M.A., and Howell S.B. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J. Infect. Dis. 162 (1990) 750-752
114. Makabi-Panzu B., Lessard C., Perron S., Désormeaux A., Tremblay M., Poulin L., Beauchamp D., and Bergeron M.G. Comparison of cellular accumulation, tissue distribution, and anti-HIV activity of free and liposomal 2', 3'-dideoxycytidine. AIDS Res. Hum. Retrovir. 10 (1994) 1463-1470
115. Makabi-Panzu B., Lessard C., Beauchamp D., Desormeaux A., Poulin L., Tremblay M., and Bergeron M.G. Uptake and binding of liposomal 2', 3'- dideoxycytidine by RAW 264.7 cells: a three-step process. J. Acquir. Immune Defic. Syndr. Human Retrovirol. 8 (1995) 227-235
116. Makabi-Panzu B., Gourde P., Desormeaux A., and Bergeron M.G. Intracellular and serum stability of liposomal 2',3'-dideoxycytidine. Effect of lipid composition. Cell. Mol. Biol. (Noisy-le-grand) 44 (1998) 277-284
117. Rossi L., Brandi G., Schiavano G.F., Chiarantini L., Albano A., and Magnani M. In vitro and in vivo toxicity of 2', 3'-dideoxycytidine in mice. Chem. Biol. Interact. 85 (1992) 255-263
118. Oussoren C., Magnani M., Fraternale A., Casabianca A., Chiarantini L., Ingebrigsten R., Underberg W.J., and Storm G. Liposomes as carriers of the antiretroviral agent dideoxycytidine-50-triphosphate. Int. J. Pharm. 180 (1999) 261-270
119. Gagne J.F., Desormeaux A., Perron S., Tremblay M.J., and Bergeron M.G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta 1558 (2002) 198-210
120. Kinman L., Brodie S.J., Tsai C.C., Bui T., Larsen K., Schmidt A., Anderson D., Morton W.R., Hu S.L., and Ho R.J. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J. Acquir. Immune. Defic. Syndr. 34 (2003) 387-397
121. Kapitza S.B., Michel B.R., van Hoogevest P., Leigh M.L., and Imanidis G. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. Eur. J. Pharm. Biopharm. 66 (2007) 146-158
122. Müller R.H., Mlangder K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000) 161-178
123. Mehnert W., and Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001) 165-196
124. Date A.A., Joshi M.D., and Patravale V.B. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 505-521
125. Bummer P.M. Physical chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles. Crit. Rev. Ther. Drug Carrier Syst. 21 (2004) 1-20
126. Manjunath K., Reddy J.S., and Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol. 27 (2005) 127-144
127. Mueller R.H., Radtke M., and Wissing S. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54 Suppl. 1 (2002) S131-S155
128. Shahgaldian P., Da Silva E., Coleman A.W., Rather B., and Zaworotko M.J. Para-acyl-calix-arene based solid lipid nanoparticles (SLN): a detailed study of preparation and stability parameters. Int. J. Pharm. 253 (2003) 23-38
129. Müller R., Dingler A., Schneppe T., and Gohla S. Large scale production of solid lipid nanoparticles (SLN) and nanosuspensions (DissoCubes). In: Wise D. (Ed). Handbook of Pharmaceutical Controlled Release Technology (2000) 359-376
130. Gohla S.H., and Dingler A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie 56 (2001) 61-63
131. Marengo E., Cavalli R., Caputo O., Rodriguez L., and Gasco M. Scale-up of the preparation process of solid lipid nanospheres: part I. Int. J. Pharm. 205 (2000) 3-13
132. Heiati H., Tawashi R., Shivers R.R., and Phillips N.C. Solid lipid nanoparticles as drug carriers I. Incorporation and retention of the lipophilic prodrug 3'-azido- 3'-deoxythymidine palmitate. Int. J. Pharm. 146 (1997) 123-131
133. Heiati H., Tawashi R., and Phillips N.C. Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate in mice. Int. J. Pharm. 174 (1998) 71-80
134. Mainardes R.M., Gremião M.P., Brunetti I.L., da Fonseca L.M., and Khalil N.M. Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 98 (2009) 257-267
135. Kuo Y.C., and Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 351 (2008) 271-281
136. Kuo Y.C. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 290 (2005) 161-172
137. Chattopadhyay N., Zastre J., Wong H.L., Wu X.Y., and Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25 (2008) 2262-2271
138. Touitou E., Dayan N., Bergelson L., Godin B., and Eliaz M. Ethosomes novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release 65 (2000) 403-418
139. E. Touitou, Inventor. Composition of applying active substance to or through the skin. US patent 5 540 934. July 30, 1996.
140. E. Touitou, Inventor. Composition of applying active substance to or through the skin, US patent 5 716 638. October 2, 1998.
141. Touitou E., Godin B., Dayan N., Weiss C., Piliponsky A., and Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. Biomaterials 22 (2001) 3053-3059
142. Dubey V., Mishra D., Nahar M., and Jain N.K. Vesicles as tools for the modulation of skin permeability. Expert Opin. Drug Deliv. 4 (2007) 579-593
143. Dayan N., and Touitou E. Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes. Biomaterials 21 (2000) 1879-1885
144. Jain S., Umamaheshwari R.B., Bhadra D., and Jain N.K. Ethosomes: a novel vesicular carrier for enhanced transdermal delivery of an anti-HIV agent. Indian J. Pharm. Sci. 66 (2004) 72-81
145. Jain S., Tiwary A.K., Sapra B., and Jain N.K. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech 8 (2007) E1-E9
146. Sarker D.K. Engineering of nanoemulsions for drug delivery. Cur. Drug Deliv. 2 (2005) 297-310
147. Tadros T., Izquierdo P., Esquena J., and Solans C. Formation and stability of nano-emulsions. Adv. Colloid Interface Sci. 109 (2004) 303-318
148. Constantinides P.P., Chaubal M.V., and Shorr R. Advances in lipid nano-dispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60 (2008) 757-767
149. Vyas T.K., Shahiwala A., and Amiji M.M. Improved oral bioavailability and brain transport of saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 347 (2008) 93-101
150. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19 (2002) 875-880
151. Pereira M., de Oliveira E., Garcion N.V., Benoit J.P., Couet W., and Olivier J.C. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. Pharm. Res. 22 (2005) 1898-1905
152. Berry C.C. Intracellular delivery of nanoparticles via HIV-1 tat peptide. Nanomedicine 3 (2008) 357-365
153. Wan L., Zhang X., Gunaseelan S., Pooyan S., Debrah O., Leibowitz M.J., Rabson A.B., Stein S., and Sinko P.J. Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res. Ther. 3 (2006) 12
154. Van Eerdenbrugh B., Froyen L., Martens J.A., Blaton N., Augustijns P., Brewster M., and Van den Mooter G. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 338 (2007) 198-206
155. Baerta L., van't Kloostera G., Dries W., François M., Wouters A., Basstanie E., Iterbeke K., Stappers F., Stevens P., Schueller L., Van Remoortere P., Kraus G., Wigerinck P., and Rosier J. Development of a long-acting injectable with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72 (2009) 502-508